Skip to main content

Home/ Medicine & Healthcare/ Group items tagged basalcellcarcinoma imiquimod

Rss Feed Group items tagged

avivajazz  jazzaviva

Imiquimod cream (Aldara) for superficial basal cell carcinoma: NPS - Better choices, Be... - 0 views

  •  
    Imiquimod cream (Aldara) for superficial basal cell carcinoma
avivajazz  jazzaviva

Use of 5% imiquimod cream in the treatment of facial basal cell carcinoma: A 3-year re... - 0 views

  •  
    PDF, Free full text article... We found that 5% imiquimod cream is aneffective treatment option for superficial and nodularbasal cell carcinomas, giving a clearance rate of89.5% at an average of 39 months of follow up.  
    Dr Yin Vun, Siller Medical, 9th Floor, SilvertonPlace, 101 Wickham Terrace, Brisbane, Qld 4000, Australia.
avivajazz  jazzaviva

New Skin Cancer Treatment Approved - Skin Diseases, Conditions, Symptoms, and Procedure... - 0 views

  •  
    79% of patients had no evidence of their sBCC at two years after finishing treatment.
avivajazz  jazzaviva

Aldara (tm) [imiquimod] Cream ~ Full Prescribing Information ~ FDA / Package Insert - 0 views

  •  
    FDA-approval: 
    * Biopsy-confirmed, primary superficial basal cell carcinoma (sBCC) in immunocompetent adults; maximum tumor diameter of 2.0 cm on trunk, neck, or extremities (excluding hands and feet), only when surgical methods are medically less appropriate and patient follow-up can be reasonably assured (1.2)
avivajazz  jazzaviva

Superficial basal cell carcinoma on face treated with 5% imiquimod cream Malhotra AK, B... - 0 views

  •  
    The precise mechanism of the anti-tumor effect of imiquimod in BCC is not known. It has been postulated that ultraviolet radiation induces mutations in the tumor-suppressor genes and alters the immuno-surveillance, so that tumor cells escape from cytotoxic T cells and apoptosis.[1] Th-2 cytokines, that downregulate tumor surveillance, are raised in BCC.[1],[5] Imiquimod acts on toll-like receptor-7 (TLR-7) present on dendritic cells, macrophages and monocytes and induces expression of interferons, Th-1 cytokines (IL-1, IL-6, IL-10 and IL-12), tumor necrosis factor-a and G-CSF, thereby counteracting Th2 cytokines and promoting tumor surveillance.[1],[5] It also enhances the activity of natural killer cells and epidermal Langerhans' cells. The tumor regression is achieved probably by induction of Fas receptors on the tumor cells resulting in their apoptosis.[10]
avivajazz  jazzaviva

Treatment of Cutaneous Tumors with Topical 5% Imiquimod Cream | Alessi SS, et al | CLIN... - 0 views

    • avivajazz  jazzaviva
       
      For patients without comorbidities, our study revealed good cure rates for superficial BCC and superficial/nodular BCC (88% and 85%, respectively). Nodular and aggressive BCC and Bowen's disease exhibited lower cure rates (50%, 50%, and 57%, respectively). I
  •  
    For patients without comorbidities, our study revealed good cure rates for superficial BCC and superficial/nodular BCC (88% and 85%, respectively). Nodular and aggressive BCC and Bowen's disease exhibited lower cure rates (50%, 50%, and 57%, respectively). I
avivajazz  jazzaviva

Recurrence rate of superficial basal cell carcinoma following successful treatment with... - 0 views

  •  
    The initial sBCC clearance rate was 90% (12-week post treatment), whereas the proportion of subjects who were clinically clear at 2 years (current time point) was estimated to be 79.4%. 
avivajazz  jazzaviva

Recurrence rate of superficial basal cell carcinom... [Eur J Dermatol. 2005 Sep-Oct] - ... - 0 views

  •  
    The initial sBCC clearance rate was 90% (12-week post treatment), whereas the proportion of subjects who were clinically clear at 2 years (current time point) was estimated to be 79.4%.
avivajazz  jazzaviva

Superficial basal cell carcinoma treated with imiquimod 5% topical cream for a 4-week p... - 0 views

  •  
    Clinical clearance rate at 1 and 2 years were 89% and 85%, respectively.
avivajazz  jazzaviva

Has imiquimod 5% cream a role in the management of... [Eur J Dermatol. 2009 Sep-Oct] - ... - 0 views

  •  
    Clinical clearance rate at 1, 2 and 3 years were 94, 76 and 70%, respectively. We conclude that imiquimod seems to be an appropriate therapeutic alternative for the treatment of recurrent BCC in patients with associated co-morbidities.
avivajazz  jazzaviva

Two-year interim results from a 5-year study evalu... [Australas J Dermatol. 2006] - Pu... - 0 views

  •  
    The proportion of subjects who were clinically clear at the 2-year follow-up visit was estimated to be 82.0%. Imiquimod was tolerated when applied daily, with erythema reported for all subjects participating in the study. The recurrence rate observed suggests that once daily dosing and 5x/week dosing yield similar clearance rates, but daily dosing increases local skin reactions.
avivajazz  jazzaviva

Use of 5% imiquimod cream in the treatment of faci... [Australas J Dermatol. 2006] - Pu... - 0 views

  •  
    We found that 5% imiquimod cream is an effective treatment option for superficial and nodular basal cell carcinomas, giving a clearance rate of 89.5% at an average of 39 months of follow up.
avivajazz  jazzaviva

Management of superficial basal cell carcinoma: focus on imiquimod ~ 2009 - 0 views

  •  
    Raasch B. Clinical, Cosmetic and Investigational Dermatology. 9 June 2009. 
    There is reasonable evidence that the use of imiquimod for small (<2 cm) superficial BCC that occur other than on the face provides 
    outcomes only marginally less satisfactory t
avivajazz  jazzaviva

Management of superficial basal cell carcinoma: focus on imiquimod - 0 views

  •  
    There is reasonable evidence that the use of imiquimod for small (<2 cm) superficial BCC that occur other than on the face provides outcomes only marginally less satisfactory than surgery. There would be a place for imiquimod in treating patients with frequent multiple primary lesions when access to surgery is difficult or where clinical judgment may be influenced by patient factors as reported in some of the studies, eg, where patients may have contraindications to surgery.  It was noted that if recurrences occurred in this study they mostly occurred during the first 9 months after the end of treatment. The initial response was therefore predictive of long-term outcome so these authors recommend and encourage continued monitoring of skin lesions.
1 - 20 of 37 Next ›
Showing 20 items per page